Junshi Biosciences Announces Completion of Enrollment in Phase I Trial of SARS-CoV-2 Neutralizing Antibody JS016
Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus.
Read more
Junshi Biosciences Receives Orphan Drug Designation from the U.S. FDA for Toripalimab
Combination with Pfizer’s Axitinib for the Treatment of Mucosal Melanoma SHANGHAI, China, March 30, 2020 (GLOBE NEWSWIRE) — Junshi Biosciences…